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NON-PARTICIPATION BIAS IN HEALTH SERVICES
RESEARCH USING DATA FROM AN INTEGRATED
ELECTRONIC PRESCRIBING PROJECT:
THE ROLE OF INFORMED CONSENT
Gillian Bartlett*, Robyn M. Tamblyn**, Yuko Kawasumi***, Lise Poissant**** and Laurel Taylor*****
Abstract: Electronic prescribing potentially reduces adverse outcomes and provides critical information for drug safety
research but studies may be distorted by non-participation bias. 52,507 patients and 28 physicians were evaluated to
determine characteristics associated with consent status in an electronic prescribing project. Physicians with less
technology proficiency, seeing more patients, and having patients with higher fragmentation of care were less likely to
obtain consent. Older patients with complex health status, higher income, and more visits to the study physician were
more likely to consent. These systematic differences could result in significant non-participation bias for research
conducted only with consenting patients.
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SESGO POR FALTA DE PARTICIPACIÓN EN LA INVESTIGACIÓN DE LOS
SERVICIOS DE SALUD AL USAR DATOS DE UN PROYECTO INTEGRADO DE
PRESCRIPCIÓN ELECTRÓNICA: EL PAPEL DEL CONSENTIMIENTO INFORMADO
Resumen: La prescripción electrónica reduce, potencialmente, los resultados adversos. y proporciona información
crítica para una investigación segura en drogas, pero los estudios pueden ser distorsionados por un sesgo por falta de
participación. Se evaluó a 52.505 pacientes y a 28 médicos para determinar características asociadas con el estatus del
consentimiento en un proyecto de prescripción electrónica. Los médicos con menor eficiencia tecnológica, con más
cantidad de pacientes que, además, mostraban mayor fragmentación en su atención, presentaban menor opción de
obtener consentimiento. Los pacientes de más edad, con estatus de salud complejo, mayor ingreso y con más visitas al
médico a cargo, manifestaban mayor disposición a consentir. Estas diferencias sistemáticas podrían desembocar en un
sesgo significativo por falta de participación en la investigación llevada a cabo sólo con pacientes con consentimiento.
Palabras clave: consentimiento informado, sesgo por falta de consentimiento, prescripción electrónica, médicos de
atención primaria, medicación por prescripción
SESGO PELA FALTA DE PARTICIPAÇÃO NA PESQUISA DOS SERVIÇOS DE
SAÚDE AO USAR DADOS DE UM PROJETO INTEGRADO DE PRESCRIÇÃO
ELETRÔNICA: O PAPEL DO CONSENTIMENTO INFORMADO
Resumo: A prescrição eletrônica reduz potencialmente os resultados adversos e proporciona informação crítica para
uma pesquisa segura em drogas, porém os estudos podem ser destorcidos por um sesgo por falta de participação.
Avaliou-se 52.505 pacientes e a 28 médicos para determinar características associadas com o estatus do consentimento
num projeto de prescrição eletrônica. Os médicos com menor eficiência tecnológica, com mais quantidade de pacientes
que os outros, mostravam maior fragmentação em sua atenção, apresentavam menos opção para conseguir o
consentimento. Os pacientes mais idosos, com estudos de saúde maiôs complexos, maiores salários e com mais visitas
ao médico, manifestavam maior disposição de consentir. Estas diferenças sistemáticas poderiam desembocar num erro
significativo por falta de participação na pesquisa levada a cabo somente com pacientes que consentiram.
Palavras chave: consentimento informado; erro por falta de consentimento; prescrição eletrônica; médicos de atenção
primária; medicação por prescrição.
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Introduction
In our current era of expanding utilization
of technology in health care, information from
health care encounters is increasingly being
recorded electronically(1,2). Integrated
electronic prescribing systems provide a new
set of tools that allow timely information to be
used to improve the safety and effectiveness of
prescribing decisions(3-8). An advantage of
integrated prescribing systems compared to
traditional methods is that information is readily
available to health professionals as patients
enter and re-enter the health care system. In
addition, these systems provide decision
support, alerts and reminders for care options
that improve prescribing choices and patient
care(9-11).  Medical conditions that pose a
health danger can be permanently flagged in
an electronic environment to greatly reduce or
eliminate medical errors(5, 8, 11-14).
As well, integrated electronic prescribing
systems provide a wealth of information from
diverse sources including administrative
records, private community pharmacy records
and the electronic prescribing application
database(4, 9). Clinical, health services and
population health research, which normally
relies on painstaking data collection on samples
of the population to address questions that are
crucial in defining optimal therapeutic
treatment, adverse drug reactions and evidence-
based decision making, can benefit greatly from
improved access to this data(1, 14, 15). While
the computerization and coding of prescription
and health information is an important resource
for researchers as well as clinicians, the
realization of the benefits of such a system will
be restricted to those patients who consent to
their prescription records being released to their
treating physician. If a patient does not provide
this consent, either because they truly do not
want to release their records or they are not
offered the opportunity to participate by the
physician, then these «non-consenting» patients
will not experience direct benefits from the
system. Furthermore, any research that is
restricted to the data collected on the consenting
patients will include a certain amount of bias
due to non-participation. The degree and
magnitude of this bias will depend on whether
participants are significantly different from non-
participants(16).
Studies of bias introduced by authorization
for the secondary use of information from
electronic health records provide some insight
into the type and magnitude of bias that may be
introduced by the informed consent process. In
Minnesota, legislation was passed in 1977 that
required a signed general authorization to release
medical records for research purposes
(Minnesota Statute 144.335: «Patient Consent
to Release Records»). Studies of the impact of
this legislation found higher refusal rates for
some sub-groups, such as middle aged or
younger patients, women and patients with
mental health concerns(17, 18). When the
potential effects of authorization bias were
studied in a Mayo Clinic, researchers found a
refusal rate of 20.7% with higher rates for
younger women and patients with sensitive
diagnoses(18). These findings have been
substantiated in urban family practice centers(19)
and hospital settings where researchers
determined that more severely ill patients are
more likely to refuse or not be approached about
consent(20). Other studies examining the role
of socioeconomic status and patient education
indicate that the informed consent process may
be limiting research to more affluent or better
educated patients(21-23).
Another factor that may play a role in
obtaining patient consent includes the role of the
physician(21, 22, 24, 25). For example, the
availability of an extensive prescription drug
profile may cause physicians to preferentially
enroll patients that they see on a regular basis or
Acta Bioethica  2005; 11 (2)
147
for whom records are available (i.e. publicly
insured patients whose records are provided by
the administrative database and are more
complete). Physicians may also be unwilling to
offer patients the opportunity to participate if they
do not see themselves as the «responsible»
physician for the drug management(11). This has
been illustrated in a Dutch study, in which
physicians varied in their perception of
responsibility for their patients’ treatment
regimens(26). This variation in responsibility
will likely have an impact on the effort made by
the physicians when recruiting patients. Obtaining
informed consent from a patient often places a
significant burden on physicians and this may be
a critical factor in determining how many patients
are even approached by the physician(21,24,25).
This appears to be particularly true for the case of
single, acute consultations(21).
To date, a detailed investigation of the
characteristics of patients who consent versus
those who do not for projects that involve the
use of information technology has not been
conducted. No study that we know of has
simultaneously investigated the role of both
physicians and patients in obtaining consent.
The objective of this study was to evaluate the
characteristics of patients, physicians and their
relationship that determines participation in a
research project utilizing an integrated
electronic prescribing system.
Methods
The MOXXI System
The Medical Office of the Twenty First
Century (MOXXI), a prototype for a fully
integrated electronic prescription system, links
information from primary care physicians and
retail pharmacies for patients in a geographically
circumscribed area in Montreal, Canada.
Physicians are equipped with wireless mobile
personal digital assistants (PDA) and given the
MOXXI system with access to complete
prescription information for consenting patients.
This provides a significant added value to
physicians as 40% of prescriptions are written
by other physicians (data provided by IMS
Canada, 1999)(27). Patient information is
retrieved by real-time integration with the
beneficiary, prescription and medical services
claims files of the provincial health insurance
board and with private pharmacy computer
networks.
Study Design & Population
This study was conducted with family
physicians who agreed to participate in the
MOXXI III trial. Eligible physicians were 30
years of age or older, in full-time, community
based fee-for-service practice. Patient consent
documents and brochures were delivered to the
28 participating physicians starting in June,
2002. The date the documents were delivered
was considered the beginning of the enrollment
period and the end of the enrollment period was
September 1, 2003. The physician’s practice
population was defined using medical services
claims and thus potentially eligible patients who
could grant access to prescription information
were identified. Eligible patients were persons
who had made at least one visit to the study
physician during the enrollment period. As the
MOXXI integrated electronic prescribing
systems uses information from Quebec
provincial administrative databases as well as
pharmacies and community based physicians,
access was granted to denominalized patient
information by the provincial Privacy
Commissioner (Commission d’accès à
l’information). Consenting patients were
assigned to the participating physician to whom
they gave the first consent and the date of the
consent was recorded electronically. Non-
consenting patients were assigned using
medical billing information to determine the
first participating physician visited after the
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beginning of the enrollment period. For non-
consenting patients within a physician’s
practice, prescription and medical services
information from administrative databases were
available in a de-identified format. Ethics
approval for the study was provided by the
McGill Faculty of Medicine Institutional
Review Board.
Measurement
Physician characteristics included factors
that may place constraints on the physicians’ time
(number of practice settings, number of patients
seen in a day) as well as the physicians’ facility
with the electronic prescribing system (ease of
use, intentions to use the system, familiarity with
computers). The number of practice settings was
measured using codes from the medical billing
databases, patient volume measured as the
number of patients with a medical visit divided
by number of distinct days with at least one
billing for a medical visit. Computer efficacy was
measured by a physician’s ease of use with the
system, intention to use the system, and general
computer self-efficacy. Ease of use with the
MOXXI system was based on the time the
physician took to complete a standardized task
performed two weeks after the physician started
using the system. For this task the physician was
required to write three new prescriptions using
the electronic pad. The intention to use the system
and computer self-efficacy (familiarity and
comfort using computers) was measured using
questions from the Technology Acceptance
Model(28,29) rated using a 5-point Likert scale
with opinion descriptors («1» for strongly
disagree and «5» for strongly agree). The
questionnaire was available on-line through the
personal digital assistants (PDA), and study
physicians completed the questionnaire after a
3-hour training session.
Patient-physician relationship characteristics
were measured to identify mutual characteristics
that might influence consent status. In Quebec,
there are two official languages, French and
English. To measure potential communications
difficulties, a physician and a patient with the same
primary language preference (French-French or
English-English) were considered to have
concordance of primary language. Concordance
for gender was also assessed based on the sex of
the study physician and their patients.
Patient characteristics that might influence
consent included demographic variables (age
and socioeconomic status), health status
(comorbidities, severity of illness), continuity
of care (how often the patient visited other
family physicians), and summaries of
prescription medication use (counts of unique
medications as well as medications used to treat
mental health problems or medications with a
potential for misuse/abuse). Age was measured
categorically (to protect patient identification
no date of birth was available for non-
consenting patients) and postal codes were used
to obtain census approximations for household
income(30). Co-morbidity and severity of
illness were assessed 6 months before the start
of the enrollment period using diagnostic codes
recorded in medical service claims and
hospitalization discharge records to determine
the Charlson comorbidity index(31-33),
number of specialists visited and the number of
emergency room visits. Continuity of care was
measured by the number of non-participating
family physician visits made by the eligible
patients using algorithms developed by the co-
investigators (34). For patients with continuous
public drug insurance, information on
prescription medication use was summarized.
This included a count of the number unique
medications dispensed from all prescribing
physicians during the enrollment period and
whether a patient was dispensed a medication
of potential abuse/misuse or a medication used
to treat a mental health problem(35,36).
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Medications of potential abuse and/or misuse
included opioids (narcotics), barbiturates,
benzodiazepines and amphetamines as
classified using the American Hospital
Formulary (AHF codes 28:08:08; 28:08:12;
28:12:04; 28:12:08; 28:20). Medications used
to treat mental health problems included anti-
depressants, anti-psychotics and lithium (AHF
codes 28:16:04; 28:16:08; 28:28).
Data Sources
Three data sources were used to assess
potential predictors of consent. First, the
provincial health insurance board (Régie de
l’assurance maladie du Québec: RAMQ) and
the Ministry of Health administrative databases
were used to assess service use and beneficiary
characteristics. The validity of these databases
has been previously established for healthcare
research(37-39). The RAMQ beneficiary
demographic database provided data on age,
sex, postal-code linked data on income and
education based on 2001 Statistics Canada
enumeration area mapping(30), patient
language preference and prescription drug
insurance status. The medical services claims
database provided information on the
beneficiary, date, type, provider, and location
of service delivery (e.g. inpatient, emergency,
clinic) for all medical services remunerated on
a fee-for-service basis (approximately 86% of
all services)(40). The hospitalization database
provided admitting and discharge diagnoses for
all acute care hospitalizations in Quebec based
on medical archivist review and coding of the
hospital record. The prescription claims
database and retail pharmacy data provided
information on each drug dispensed including
the drug name, quantity, date and duration for
each prescription, the prescribing physician,
and the dispensing pharmacy. Second, data on
consent status and physician responses to on-
line questionnaires was retrieved from the
MOXXI server. Data from all sources are linked
by an encrypted health insurance number
(RAMQ number), a unique identifier for each
Quebec resident, with a look-up table for all
consenting patients. Finally, physician
demographics were provided by RAMQ and
the Quebec College of Physicians (Collège des
Médecins du Québec) and include sex, language
preference, location of graduating medical
school, year of graduation, and medical
specialty. Physician data was linked through the
medical license number. The occurrence of
visits to the study physician during the study
period was determined by information retrieved
from medical services claims database. The
existence of one or more prescriptions during
follow-up was determined from the pharmacy
records retrieved for each patient daily from the
RAMQ and retail pharmacies.
Statistical Analyses
Frequency distributions of physician and
patient characteristics were determined and the
means, standard deviations (sd) and ranges were
reported for continuous variables (p-values
were not reported as the large sample size would
make even minor differences statistically
significant). Multivariate logistic generalized
estimating equations (GEE) were used to
investigate whether patient or physician
characteristics increased the probability of
consenting to participate. Patients were
clustered within physicians with an
exchangeable correlation structure. The unit of
analysis was the patient (with positive consent
status as the outcome of interest). Statistical
analyses were conducted using SAS 9.1.
Results
During the enrollment period, the study
physicians saw 52,444 distinct patients. Patients
who were seen only in locations other than the
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community-based office were excluded, and
52,507 patients were eligible to be enrolled in
the MOXXI study and 11,954 (26.9%)
consented to participate. Almost half of the
participating physicians were female (46.4%)
and 78.5% indicated that their primary language
preference was French. Table 1 presents the
characteristics and description of practice
settings for the study physicians. Enrolment
rates varied greatly among the physicians, from
8.8% to almost 75% with the length of the
enrollment period lasting an average of one and
a half years. Other locations where the
physicians might practice besides the
community-based office included drop-in
clinics, emergency rooms, hospital out-patient
clinics and nursing homes.
Table 1.  Description of the characteristics and practice setting for study physicians (N=28) during the
enrollment period (starting June 2002 to August 2003).
Mean (sd) Median Range
Practice Setting Characteristics
Number of practice settings 1.8 (1.1) 1.5 1 - 5
Total number of unique patients with a clinic visit 2,472.8 (1340.4) 2,216.5 650-4,770
No of patients seen by physician per clinic day* 23.7 (5.9) 23.6 13.4-36.1
Technology Efficacy
No of minutes to complete standardized task 2.0 (0.97) 1.7 0.4 - 4.5
Intention to Use the MOXXI System† 4.3 (0.8) 5 2 - 5
Computer Self-Efficacy† 4.0 (0.8) 4 2 - 5
Consent Rates
% unique patients who signed a consent form 26.9 (18.9) 18.6 8.8 - 75.3
Length of enrollment period in days 411.6 (71.2) 438 203 - 448
* A clinic day is counted if the physician billed for at least one clinic visit for that day.
† Self-report questionnaire measured on a 5-point scale where «5» indicates «Strongly Agree» and «1» indicates
«Strongly Disagree».
Table 2 presents the characteristics of patients
who consented and patients who were not
approached or who refused to consent.
Consenting patients tended to be older, have a
higher household income, have a higher
severity of illness and have greater continuity
of care. On average, patients who consented
saw their study physician almost two and a half
times as often compared to non-consenting
patients (mean of 4.2 visit days versus 2.0,
p>0.0001) and had almost twice as many
comorbidities (Charlson Comorbidity Index of
0.68 versus 0.34, p>.0001). The majority of
patients were primarily French-speaking
(69.8% of consenting patients and 74.6% of
non-participating patients) and over half were
female (60.1% and 54.7%, consenting and non-
participating respectively).
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Table 2.  Patients’ characteristics (N= 52,507) in relationship to consent status.
Consented (%) Not Approached or Refused to
n=11,954 Consent (%)
n=40,553
Relationship to Study Physician
Concordance for primary language* 9,350 (78.2%) 30,158 (74.3%)
Concordance for gender 6,853 (57.3%) 21,137 (52.1%)
Demographics Age (years):
≤ 18 years 477 (3.9%) 11,281 (27.8%)
   19-43 years 2,696 (22.5%) 15,166 (37.3%)
   44-63 years 5,117 (42.8%) 10,325 (25.4%)
≥ 64 years 3,664 (30.6%) 3,781 (9.3%)
Household Income (CND $)†:
≤  41,276 2,583 (21,6%) 10,594 (26.1%)
    41,277 - 51,574 2,535 (21,2%) 10,641 (26.3%)
    51,575 - 62,296 3,240 (27,1%) 9,788 (24.1%)
≥  62,297 3,596 (30,1%) 9,530 (23.5%)
Opportunities for Consent and Potential Benefit of Electronic Drug Management
Visits to study physician during enrollment:
    1 1,740 (14.5%) 23,275 (57.3%)
    2 - 3 4,168 (34.8%) 12,107 (29.8%)
    ≥ 4 6,046 (50.5%) 5,171 (12.7%)
Public drug insurance coverage:‡ 5,787 (48.4%) 15,280 (37.7%)
Comorbidity and Severity of Illness
Charlson Comorbidity Index > 0.5‡ 4,324 (36.1%) 8,957 (22.0%)
No. of specialists visited: ‡
  0 5,842 (48.8%) 26,177 (64.5%)
  1-2 5,007 (41.8%) 12,828 (31.6%)
  ≥ 3 1,105 (9.2%) 1,548 (3.8%)
No. of emergency room visits: ‡
  0 10,775 (90.1%) 36,862 (90.8%)
  1-2 549 (4.5%) 2,169 (5.3%)
  ≥ 3 630 (5.2%) 1,522 (3.7%)
Continuity of Care
No. of visits to non-study physicians: ‡
  0 8,222 (68.7%) 24,333 (60.0%)
  1-2 3,171 (26.5%) 13,543 (33.3%)
   ≥ 3 561 (4.6%) 2,677 (6.6%)
* Patient’s and physicians’ language preference is determined from administrative records that indicate the preferred
language of communication: English or French. Concordance occurs when the stated language preference is the
same for the physician and the patient.
† Household income is (Canadian $) based on census track information for 6-digit postal code.
‡ Measured for the 6 months prior to the start of the enrollment period for the patient’s study physician.
Table 3 presents the adjusted likelihood (odds
ratios with 95% confidence intervals) for patient
and physician characteristics that may have
influenced whether patients consented to
participate. All characteristics included in the model
that adjusted for clustering among physicians were
significant; however, status of public drug insurance
was collinear with patient age and was removed
from the model. The main characteristics that
positively influenced consent were patient age with
a 13-fold increase in probability, patient household
income (up to 32% increase), the number of
opportunities for consent with an 11-fold increase
in probability, the physician’s intention to use the
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system (74% increase) and severity of illness for
the patient (10% - 47% increase). The main
characteristics that negatively influenced consent
were an increase in the number of patients seen by
the study physician per clinic day, with an increase
of 5 patients decreasing the probability of
consenting by 30% and poor continuity of care with
Table 3.  The association between patient and physician characteristics and likelihood of consenting:
multivariate logistic regression analysis.
Likelihood of Consent 95% Confidence Intervals
(Odds Ratios)
Practice Setting Characteristics
Practicing in more than one setting† 1.08 1.01 - 1.15
Per 5 additional patients seen per clinic day 0.72 0.70 - 0.74
Physician’s Technology Efficacy
No. of minutes to complete standardized task 0.86 0.84 - 0.89
Intention to Use the MOXXI System‡ 1.20 1.13 - 1.25
Computer Self-Efficacy‡ 1.04 0.99 - 1.14
Patient Relationship to Study Physician
Concordance for primary language 1.22 1.15 - 1.30
Concordance for gender 1.12 1.07 - 1.18
Patient Demographics
Age (years):  ≤ 18 reference -
   19-43 3.62 3.26 - 4.02
   44-63 7.83 7.08 - 8.66
≥ 64 11.19 10.03 - 12.47
Household Income (CND $):   ≤  41,276 reference -
    41,277 - 51,574 1.09 1.02 - 1.17
    51,574 - 62,296 1.26 1.17 - 1.35
≥  62,297 1.33 1.23 - 1.43
Opportunities for Consent
Visits to study physician during enrollment:     1 reference -
    2 - 3 3.92 3.68 - 4.18
    ≥ 4 11.08 10.37 - 11.84
Patient Comorbidity and Severity of Illness
Charlson Comorbidity Index > 0.5 1.10 1.04 - 1.17
No. of specialists visited:   0 reference -
  1-2 1.28 1.22 - 1.35
  ≥ 3 1.31 1.18 - 1.46
No. of emergency room visits:   0 reference -
  1-2 1.20 1.07 - 1.36
  ≥ 3 1.46 1.27 - 1.67
Patient Continuity of Care
No. of visits to non-study physicians: ‡    0 reference -
  1-2 0.64 0.60 - 0.68
   ≥ 3 0.39 0.34 - 0.44
* Adjusted for physician level clustering using multivariate GEE modeling, values greater than one indicate increased likelihood.
† Other practice locations include emergency rooms, community drop in clinics (salaried physicians), and nursing homes.
‡ Responses were dichotomized into high and low groups (high response = 4 or 5).
more than 3 visits to other family physicians before
the enrollment period decreasing the probability
of consent by over 60%. A decrease in proficiency
with the MOXXI system as measured by the
completion of a standardized task also significantly
decreased the likelihood of obtaining consent from
a patient by 13%.
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To determine if specific patients might refuse
consent due to confidentiality issues or a desire
to withhold information, a secondary analysis
was performed on patients who had medication
information available (publicly insured). Patients
were included in this analysis if they filled at
least one prescription at a community-based
pharmacy. Selected characteristics for these
15,004 publicly insured patients are reported in
Table 4 and include the number of unique
medications dispensed and whether the patient
had ever been dispensed a medication to treat
mental health problem or a medication with a
potential for misuse or abuse. The consent rate
for these patients was 31.5% (4,756 patients).
Consenting patients were dispensed an average
of 48.5 unique medications during the enrollment
period compared to 25.3 unique medications for
non-participating patients (p<0.0001). Being
dispensed two or more unique medications
significantly increased the probability of
consenting to participate by 40%.
Table 4. Description and association of patients’ characteristics and consent status for patients with
continuous public drug insurance during enrollment (N=15,004).
Characteristics* Consented (%) Not Approached or Odds Ratios** 95% Confidence
n=4,756 Refused to Consent Interval
(%) n=10,248
Patients dispensed at least one
medication of potential
abuse/misuse during enrollment† 351 (7.4%) 652 (6.4%) 0.86 0.73 - 1.02
Patients dispensed at least one
medication used to treat mental
health problems during enrollment‡ 33 (0.7%) 66 (0.6%) 0.69 0.42 - 1.12
The number of unique medications
dispensed during enrollment:††
1 132 (2.8%) 1,180 (11.5%) reference -
2 - 6   443 (9.3%) 2,929 (28.6%) 0.97 0.76 - 1.23
7 - 18 756 (15.9%) 2,315 (22.6%) 1.40 1.10 - 1.77
>18 3,425 (72.0%) 3,824 (37.3%) 1.95 1.55 - 2.45
* Measured during the enrollment period.
† Medications of intentional abuse/misuse included opioids (narcotics), barbiturates, benzodiazepines and
amphetamines.
‡ Medications used to treat mental health problems included anti-depressants, anti-psychotics and lithium.
†† A medication was counted as one unique prescription as long as the drug and dose remained the same (i.e. 12 refills
for 10 mg tablets of Lipitor (r) would only be counted as one medication).
** Adjusted using multivariate GEE modeling for all patient, patient-physician and physician characteristics included
in the initial analysis (Table 3) except drug insurance status. The magnitude and significance of all the odds ratios
in the initial analyses remained similar except the Charlson Comorbidity Index which became non-significant (OR
0.93; 95% CI 0.85-1.03).
Discussion
This study was a unique opportunity to
compare physician characteristics in concert with
the characteristics of both participating and non-
participating patients. We found that higher
consent rates were obtained by physicians who
saw fewer patients per day (patient flow) and
who were more proficient utilizing the
technology. Consenting patients were older,
sicker, lived in areas with higher household
income levels and visited the study physician on
a more regular basis. These patients were also
more likely to be the same gender as their
The Role of Informed Consent - G. Bartlett, R. Tamblyn, Y. Kawasumi, L. Poissant and L. Taylor
154
physicians and have the same language
preference. These findings appear to support the
hypothesis that physicians enroll patients when
they perceive there to be value-added benefits
to patient management, i.e. older patients with
more complex prescription drug histories. The
strongest predictor of consent was the number
of visits the patient made to the study physician.
This emphasizes the physician’s role in providing
the opportunity for patients to consent as well as
the physician’s perception of their role as the
physician most responsible for the care of that
patient(26,41,42). Physicians who saw more
patients in a day and were not as proficient in
utilizing the technology were less likely to obtain
consent from their patients. Thus, the importance
of the role of the physician in obtaining patient
consent is apparent particularly when the range
of consent rates is examined by individual
physician (9 to 75%, Table 1).
For the patients who did not consent, we are
unable to determine if the patient was
approached by the physician to obtain consent
and declined, or whether the patient was never
approached. However, a time and motion study
completed by one of the authors (LP) provided
evidence that physicians were preferentially
selecting patients to approach regarding
participation in the project. This study was
conducted among 14 physicians participating
in the MOXXI project to estimate the time and
method by which an integrated drug
management system would be used in their
clinical practice. Available data on 315 patient-
physician encounters indicate that only 45% of
the patients were asked to participate in the
research project. Of these, 6% refused and 18%
requested that the physician ask them again at
a later date. The average duration of a clinic
visit was 13.9 minutes (sd 8.8 minutes) and
approaching patients for consent to participate
in the study required, on average, 1.5 minutes
(sd 1.3 minutes). Excluding patients who were
already participating in the study, a total of 48%
of patients were not asked to consent. Anecdotal
evidence from physicians indicate that they
recruit patients «who are our regular patients»
supporting previous expectations that
physicians do not seek consent for patients who
receive more fragmented care(26,41,42). While
a preliminary analysis of the data from the time
and motion study indicated that there was no
clear association between mean duration of the
clinical encounters and patient recruitment rates
for physicians, our findings indicate that an
increase in the patient flow (number of patients
seen in a day) significantly decreases the
probability of obtaining consent (odds ratio 0.72
per 5 additional patients; 95% CI 0.70-0.74).
We attempted to determine whether the use
of medications for mental health problems or
those that have the potential for abuse or misuse
play a role in determining patient consent. From
previous studies by Jacobsen et al.(18) and
Yawn et al.(17) that found patients with more
sensitive diagnosis or mental health problems
were less likely to consent, we expected to find
a difference in rate of medication use between
consenting and non-consenting patients.
However, our study did not have enough
patients who were dispensed these types of
medications to allow for clinical or statistical
significance. Ideally, to examine the role of
medications with the potential for misuse or
abuse in determining participation, the patterns
of use should be evaluated to identify excessive
or escalating use over time(35, 43, 44). This
would require a far larger sample accrued over
a longer period of time than was available for
this study. A larger sample would also be
necessary to evaluate the medications used to
treat mental health problems. In our study, only
88 patients (0,6 %) with public drug insurance
were dispensed an anti-depressant, an anti-
psychotic or a prescription for lithium. These
relatively low rates may be due to the age of
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the insured population who were mostly greater
than 65 years old as well as the geographical
location of the pilot study, a suburban area of a
large metropolitan city with relatively high
socioeconomic status(45). The MOXXI project
is currently expanding to include additional
physicians and patients from more
geographically diverse areas with lower
socioeconomic levels. This expansion will
allow us to further investigate what, if any, role
these medications play in determining patient
participation.
Based on the findings of our study, physician
and patient characteristics play an important
role in determining the probability of patient
consent to participate in an electronic
prescribing project. More importantly, patients
who consent to participate are significantly and
systematically different than patients who are
not approached or who refuse consent. These
non-trivial differences that are often related to
important health outcomes would introduce
serious bias in any research that was restricted
to consenting patients.
While informed consent plays a critical role
in the protection of a patient’s rights to privacy
and confidentiality, there is considerable debate
centered on how to best inform patients with
respect to the potential use of their data and
whether patients must, need or want to provide
explicit consent for both clinical care and health
care research(46-51). This is a critical issue for
public health as adverse drug events are
estimated to be the sixth leading cause of
mortality in the United States(52). This has
created an urgent need for rigorous and
systematic post-market surveillance for
prescription medications(53,54). Integrated
electronic prescribing systems offer an
unprecedented opportunity to capture timely
information regarding drug safety and quality
to address this issue. However this process may
be biased if obtaining informed patient consent
is required for the use of this patient-specific
data. Furthermore, if certain physician
characteristics are pivotal in acquiring informed
consent, as suggested by our findings, we run
the risk of obtaining a technically informed but
uneducated consent(51). Future research should
focus on new models of patient consent that
balance the rights of individuals for privacy and
confidentiality with the requirements of public
health research.
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